Pulmonx Corporation (NASDAQ:LUNG) Short Interest Down 49.2% in June

Posted by George Bondi on Jul 15th, 2026

Pulmonx Corporation (NASDAQ:LUNG – Get Free Report) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 1,148,892 shares, a decrease of 49.2% from the June 15th total of 2,263,505 shares. Based on an average daily trading volume, of 862,593 shares, the short-interest ratio is presently 1.3 days. Approximately 2.9% of the shares of the company are sold short.

Pulmonx Stock Performance

LUNG traded down $0.05 during trading on Wednesday, reaching $1.43. The company’s stock had a trading volume of 66,217 shares, compared to its average volume of 475,469. The company has a debt-to-equity ratio of 0.81, a quick ratio of 4.04 and a current ratio of 4.91. The company’s fifty day moving average price is $1.42 and its 200-day moving average price is $1.54. Pulmonx has a 52-week low of $1.13 and a 52-week high of $3.88. The company has a market capitalization of $60.40 million, a price-to-earnings ratio of -1.10 and a beta of 0.30.

Pulmonx (NASDAQ:LUNG – Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.33). The business had revenue of $20.59 million during the quarter, compared to the consensus estimate of $20.43 million. Pulmonx had a negative return on equity of 92.94% and a negative net margin of 60.09%. On average, equities analysts forecast that Pulmonx will post -1.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Cerity Partners LLC acquired a new stake in Pulmonx in the fourth quarter valued at $27,000. Opal Capital LLC acquired a new position in shares of Pulmonx during the 4th quarter worth $29,000. Regatta Capital Group LLC acquired a new position in shares of Pulmonx during the 4th quarter worth $30,000. Lazard Asset Management LLC acquired a new position in shares of Pulmonx during the 4th quarter worth $31,000. Finally, FNY Investment Advisers LLC purchased a new position in shares of Pulmonx in the 3rd quarter valued at about $29,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Wall Street Analysts Forecast Growth

LUNG has been the topic of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a report on Monday. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Pulmonx in a research note on Thursday, April 30th. Finally, Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $5.58.

View Our Latest Stock Report on Pulmonx

About Pulmonx

(Get Free Report)

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.